Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer | Zendy

Howard I. Scher | Zendy; Glenn Heller | Zendy; Arturo Molina | Zendy; Gerhardt Attard | Zendy; Daniel C. Danila | Zendy; Xiaoyu Jia | Zendy; Weimin Peng | Zendy; Shahneen Sandhu | Zendy; David Olmos | Zendy; Ruth Riisnaes | Zendy; Robert G. McCormack | Zendy; Tomasz Burzykowski | Zendy; Thian Kheoh | Zendy; Martin Fleisher | Zendy; Marc Buyse | Zendy; Johann S. de Bono | Zendy

Open Access

Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Howard I. Scher,

Glenn Heller,

Arturo Molina,

Gerhardt Attard,

Daniel C. Danila,

Xiaoyu Jia,

Weimin Peng,

Shahneen Sandhu,

David Olmos,

Ruth Riisnaes,

Robert G. McCormack,

Tomasz Burzykowski,

Thian Kheoh,

Martin Fleisher,

Marc Buyse,

Johann S. de Bono

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.55.3487

Subject(s) - medicine , prostate cancer , abiraterone acetate , oncology , prednisone , biomarker , surrogate endpoint , docetaxel , circulating tumor cell , cancer , urology , metastasis , androgen deprivation therapy , biochemistry , chemistry

Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration as a surrogate outcome measure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research